OUTCOMES OF SUBSEQUENT TREATMENT AFTER ATEZOLIZUMAB–BEVACIZUMAB FOR HEPATOCELLULAR CARCINOMA. YHCĐ 2026, 67 (10). https://doi.org/10.52163/yhc.v67i10.6872.